Literature DB >> 10695871

Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause.

P M Sarrel1.   

Abstract

Investigators continue to define the exact relationship between sexual function and changes in hormonal status during menopause. The availability of different preparations that could replace estrogens and androgens has led to many studies of the use of hormone replacement therapy (HRT) for sexual dysfunction. Dyspareunia due to vaginal dryness appears to be most responsive to estrogen replacement therapy (ERT) via restoration of vaginal cells, pH, and blood flow. Progestins, to a certain extent, can oppose these changes and lead to a recurrence of dryness and dyspareunia. ERT has also been reported to enhance sexual desire in a significant percent of women. Although treatment with ERT has been shown to be efficacious for many women, there are others whose sexual difficulties remain unresponsive. There also appears to be a significant subgroup of women whose sexual difficulties respond initially to ERT but who subsequently revert to their initial problems, especially when the problem has been loss of libido. For these women, the addition of androgen has proved helpful.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10695871     DOI: 10.1089/152460900318830

Source DB:  PubMed          Journal:  J Womens Health Gend Based Med        ISSN: 1524-6094


  8 in total

1.  Local Effects of Vaginally Administered Estrogen Therapy: A Review.

Authors:  Megan Krause; Thomas L Wheeler; Thomas E Snyder; Holly E Richter
Journal:  J Pelvic Med Surg       Date:  2009-05

Review 2.  Dyspareunia in postmenopausal women: a critical review.

Authors:  A Kao; Y M Binik; A Kapuscinski; S Khalife
Journal:  Pain Res Manag       Date:  2008 May-Jun       Impact factor: 3.037

3.  The roles of testosterone and alpha-amylase in exercise-induced sexual arousal in women.

Authors:  Lisa Dawn Hamilton; Emily A Fogle; Cindy M Meston
Journal:  J Sex Med       Date:  2008-01-21       Impact factor: 3.802

Review 4.  Potential future options in the pharmacotherapy of female sexual dysfunction.

Authors:  Stefan Uckert; Margit E Mayer; Udo Jonas; Christian G Stief
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

5.  Estrogenic activity of friedelin rich fraction (IND-HE) separated from Cissus quadrangularis and its effect on female sexual function.

Authors:  Urmila M Aswar; S Bhaskaran; V Mohan; Subhash L Bodhankar
Journal:  Pharmacognosy Res       Date:  2010-05

6.  Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy.

Authors:  C Derzko; S Elliott; W Lam
Journal:  Curr Oncol       Date:  2007-12       Impact factor: 3.677

7.  Prevalence of female sexual dysfunction among Indian fertile females.

Authors:  Vineet V Mishra; Sakshi Nanda; Bhumika Vyas; Rohina Aggarwal; Sumesh Choudhary; Suwa Ram Saini
Journal:  J Midlife Health       Date:  2016 Oct-Dec

8.  Evaluation of Sexual Function in Women with Hypogonadotropic Hypogonadism Using the Female Sexual Function Index (FSFI) and the Beck Depression Inventory (BDI).

Authors:  Mert Ulaş Barut; Hakan Çoksüer; Sibel Sak; Murat Bozkurt; Elif Ağaçayak; Uğur Hamurcu; Didem Kurban; Süleyman Eserdağ
Journal:  Med Sci Monit       Date:  2018-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.